BioCardia files revised FDA De Novo pre-submission for Helix catheter clearance

Bitget2026/10/01 13:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioCardia filed a revised De Novo pre-submission with the FDA for marketing clearance of its Helix catheter for heart agent delivery.
FDA previously raised no concerns on safety, performance, or broad agent compatibility in a May meeting; minutes were accepted in August.
FDA targets an initial accept-or-refuse review within 15 days; written feedback or a meeting within 70 days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010915PRIMZONEFULLFEED9837659) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioCardia files revised FDA De Novo pre-submission for Helix catheter clearance

You may also like

Crypto prices